A detailed history of New Century Advisors, LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, New Century Advisors, LLC holds 288 shares of RCUS stock, worth $4,547. This represents 0.01% of its overall portfolio holdings.

Number of Shares
288
Holding current value
$4,547
% of portfolio
0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 13, 2022

BUY
$23.23 - $30.07 $6,690 - $8,660
288 New
288 $8,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.14B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track New Century Advisors, LLC Portfolio

Follow New Century Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Century Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Century Advisors, LLC with notifications on news.